Monte Rosa Therapeutics, Inc. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase
Monte Rosa Therapeutics, Inc. (GLUE) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase of 1.25% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. defined benefit plan, assumptions used calculating net periodic benefit cost, rate of compensation increase for fiscal 2025 was 1.25%, a 0.00% change from fiscal 2024.
- Monte Rosa Therapeutics, Inc. defined benefit plan, assumptions used calculating net periodic benefit cost, rate of compensation increase for fiscal 2024 was 1.25%, a 0.00% change from fiscal 2023.
- Monte Rosa Therapeutics, Inc. defined benefit plan, assumptions used calculating net periodic benefit cost, rate of compensation increase for fiscal 2023 was 1.25%, a 0.00% change from fiscal 2022.
- Monte Rosa Therapeutics, Inc. defined benefit plan, assumptions used calculating net periodic benefit cost, rate of compensation increase for fiscal 2022 was 1.25%, a 25.00% increase from fiscal 2021.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 12 month |
|---|---|
| 2025-12-31 | 1.25% 10-K · filed 2026-03-17 |
| 2024-12-31 | 1.25% 10-K · filed 2026-03-17 |
| 2023-12-31 | 1.25% 10-K · filed 2025-03-20 |
| 2022-12-31 | 1.25% 10-K · filed 2024-03-14 |
| 2021-12-31 | 1.00% 10-K · filed 2023-03-16 |
| 2020-12-31 | 1.00% 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |